Valuation: Novartis AG

Capitalization 278B 236B 216B 204B 381B 26,273B 384B 2,566B 1,000B 12,620B 1,044B 1,022B 43,570B P/E ratio 2026 *
20.1x
P/E ratio 2027 * 17x
Enterprise value 310B 264B 241B 228B 425B 29,322B 429B 2,864B 1,116B 14,084B 1,165B 1,140B 48,625B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 5.06x
Free-Float
87.85%
Yield 2026 *
3.09%
Yield 2027 * 3.23%
1 day+0.05%
1 week-2.19%
Current month-2.19%
1 month-7.22%
3 months-5.69%
6 months+11.14%
Current year+3.43%
1 week 112.84
Extreme 112.84
116.28
1 month 108.24
Extreme 108.24
121.98
Current year 107.68
Extreme 107.68
131
1 year 87.89
Extreme 87.89
131
3 years 81.1
Extreme 81.1
131
5 years 72.84
Extreme 72.84
131
10 years 65.09
Extreme 65.09
131
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 68 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5d. change 1-year change 3-years change Capi.($)
+0.05%-2.19%+24.69%+21.29% 278B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+22.40%+11.18% 324B
+0.23%-1.24%+30.31%+12.00% 282B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
-2.04%-0.24%+35.52%+66.66% 163B
Average -0.83%-0.69%+23.14%+29.44% 343.84B
Weighted average by Cap. -1.10%-1.22%+26.11%+45.29%

Financials

2026 *2027 *
Net sales 57.14B 48.55B 44.43B 41.93B 78.22B 5,397B 78.91B 527B 205B 2,592B 214B 210B 8,949B 60.59B 51.48B 47.11B 44.47B 82.95B 5,722B 83.68B 559B 218B 2,749B 227B 223B 9,490B
Net income 14.15B 12.02B 11B 10.38B 19.37B 1,336B 19.54B 130B 50.87B 642B 53.08B 51.97B 2,216B 15.8B 13.42B 12.28B 11.59B 21.62B 1,492B 21.82B 146B 56.8B 717B 59.27B 58.02B 2,474B
Net Debt 32.28B 27.42B 25.1B 23.69B 44.19B 3,048B 44.58B 298B 116B 1,464B 121B 119B 5,055B 28.28B 24.02B 21.99B 20.75B 38.71B 2,671B 39.05B 261B 102B 1,283B 106B 104B 4,429B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
08/05/26 113.36 CHF +0.05% 1,543,283
07/05/26 113.30 CHF -2.02% 2,598,547
06/05/26 115.64 CHF +1.85% 2,586,151
05/05/26 113.54 CHF -0.26% 2,529,710
04/05/26 113.84 CHF -1.78% 1,818,814
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
145.80USD
Average target price
155.32USD
Spread / Average Target
+6.53%

Quarterly revenue - Rate of surprise